Clinical trial
Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With…
NCT00047879 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00047879 |
|---|---|
| Title | Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas |
| Official title | A Phase II Study of Peg-Interferon Alpha-2B (Peg-Intron(TM)) and Thalidomide in Adults With Recurrent High-Grade Gliomas |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Glioma |
| Intervention type | Biological, Drug |
| Interventions | PEG-interferon alfa-2b, Thalidomide |
| Enrollment | 7 |
| Start date | Oct 1, 2002 |
| Primary completion | Jun 1, 2009 |
| Completion | Jun 1, 2009 |
| First posted | Oct 23, 2002 |
| Last update posted | Oct 26, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: